van Olden Rudolf W, Guchelaar Henk-Jan, Struijk Dirk G, Krediet Raymond T, Arisz Lambertus
Department of Nephrology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Perit Dial Int. 2003 Jul-Aug;23(4):339-47.
High doses of furosemide can increase urine volume in chronic peritoneal dialysis (CAPD) patients. However, no information is available about effects on urinary solute excretion in relation to residual glomerular filtration rate (GFR), urinary furosemide excretion, and peritoneal solute kinetics.
Diuretic response and the effect on peritoneal fluid and solute transport parameters were investigated in 7 stable CAPD patients with residual renal function (median urine volume 350 mL/24 hours, range 140- 1900 mL/24 hours). Comparisons were made during two clearance periods of 24 hours: one without (P1) and one during 2 g furosemide (P2).
The median increase in urine volume was 400 mL (range 270 - 910 mL, p < 0.02) and the increase in sodium excretion was 54 mmol (range 25 - 118 mmol, p < 0.02). No change in GFR was found between P1 (2.4 mL/ minute, range 0.6 - 5.7 mL/min) and P2 (2.0 mL/min, range 1.0 - 4.8 mL/min). An increase in fractional clearance was found for volume, sodium, potassium, and osmolality (p < 0.02). No change was found in the fractional clearance of urea and electrolyte-free water. Furosemide excretion in urine was 8.7 mg/24 hours (range 2.1 - 38 mg/24 hours) and in dialysate 4.9 mg/24 hours (range 1.9 - 7.8 mg/ 24 hours). Plasma furosemide concentration was 29.5 mg/L (range 6.2 - 43.9 mg/L). A positive correlation was found between residual GFR and total urine furosemide excretion (r = 0.93, p < 0.005). Efficiency, expressed as the increase in fractional sodium clearance (percent) per milligram of furosemide excreted per 24 hours, was 1.2%/mg (range 0.3% - 11.3%/mg).
High-dose furosemide is effective in CAPD patients in increasing urine volume and electrolyte excretion without affecting urea and creatinine clearance. In CAPD patients, the individual response to an identical high dose of furosemide is dependent on the magnitude of residual GFR.
高剂量呋塞米可增加慢性腹膜透析(CAPD)患者的尿量。然而,关于其对与残余肾小球滤过率(GFR)、尿呋塞米排泄及腹膜溶质动力学相关的尿溶质排泄的影响尚无相关信息。
对7例具有残余肾功能的稳定CAPD患者(24小时尿量中位数为350 mL,范围140 - 1900 mL/24小时)的利尿反应以及对腹膜液和溶质转运参数的影响进行了研究。在两个24小时清除期进行比较:一个无呋塞米(P1),另一个在使用2 g呋塞米期间(P2)。
尿量中位数增加400 mL(范围270 - 910 mL,p < 0.02),钠排泄增加54 mmol(范围25 - 118 mmol,p < 0.02)。P1期(2.4 mL/分钟,范围0.6 - 5.7 mL/分钟)和P2期(2.0 mL/分钟,范围1.0 - 4.8 mL/分钟)之间未发现GFR有变化。发现容量、钠、钾和渗透压的分数清除率增加(p < 0.02)。尿素和无电解质水的分数清除率未发现变化。尿中呋塞米排泄量为8.7 mg/24小时(范围2.1 - 38 mg/24小时),透析液中为4.9 mg/24小时(范围1.9 - 7.8 mg/24小时)。血浆呋塞米浓度为29.5 mg/L(范围6.2 - 43.9 mg/L)。发现残余GFR与尿中呋塞米总排泄量之间呈正相关(r = 0.93,p < 0.005)。以每24小时每毫克呋塞米排泄量的分数钠清除率增加百分比表示的效率为1.2%/mg(范围0.3% - 11.3%/mg)。
高剂量呋塞米对CAPD患者增加尿量和电解质排泄有效,且不影响尿素和肌酐清除率。在CAPD患者中,对相同高剂量呋塞米的个体反应取决于残余GFR的大小。